Transient and persistent neurological manifestations of migraine.
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001037:Aphasia / Q000209:etiology; D002561:Cerebrovascular Disorders / Q000209:etiology; D003221:Confusion / Q000209:etiology; D004878:Ergotamine / Q000627:therapeutic use; D005260:Female; D006212:Hallucinations / Q000209:etiology; D006429:Hemiplegia / Q000209:etiology; D006732:Horner Syndrome / Q000209:etiology; D006801:Humans; D008297:Male; D008784:Methysergide / Q000627:therapeutic use; D008881:Migraine Disorders / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D009886:Ophthalmoplegia / Q000209:etiology; D013575:Syncope / Q000209:etiology; D014717:Vertigo / Q000209:etiology; D014786:Vision Disorders / Q000209:etiology
D000318:Adrenergic beta-Agonists; D000893:Anti-Inflammatory Agents; D004878:Ergotamine; D008784:Methysergide